7-氮杂吲哚-4-硼酸酯 | 942919-26-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸酯
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 7-氮杂吲哚-4-硼酸酯
• 中文别名: 4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-1H-吡咯并[2,3-B]吡啶；7-氮杂吲哚-4-硼酸频哪醇酯
• 英文名称: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 7-azaindole-4-boronic acid pinacol ester；1H-pyrrolo[2,3-b]pyridine-4-boronic acid pinacol ester；4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine；4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole[2,3-b]pyridine
• CAS: 942919-26-8
• 化学式: C₁₃H₁₇BN₂O₂
• mdl: MFCD11616360
• 分子量: 244.101
• InChiKey: OYFHAWAVFVJOBN-UHFFFAOYSA-N

物化性质

• 密度：
  1.15
• 闪点：
  199℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.12
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C，干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1H-Pyrrolo[2,3-b]pyridine, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1H-Pyrrolo[2,3-b]pyridine, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS number: 942919-26-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H17BN2O2
Molecular weight: 244.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

7-氮杂吲哚-4-硼酸酯是一种有机中间体，可用于Suzuki金属偶联反应。

制备

7-氮杂吲哚-4-硼酸酯可由4-溴-7-氮杂吲哚为原料制备得到。具体步骤如下：

1. 将387千克乙酸异丙酯填充至容器中，并用氮气惰性化后开始搅拌。
2. 加入4-溴-7-氮杂吲哚（41.5千克，211摩尔）。
3. 添加乙酸钾（43.1千克，439摩尔）。
4. 再加入双(频哪醇合)二硼（54.7千克，215.4摩尔）和双(三苯基膦)二氯化钯(II)（2.9千克，4.13摩尔）。
5. 在85℃-90℃下加热该容器内容物22小时。
6. 将混合物冷却至50℃，用4倍量的水（共872千克）洗涤。
7. 添加27.8千克巯基二氧化硅，在50℃下加热8小时。
8. 过滤去除固体，并用乙酸异丙酯（98千克）洗涤滤饼。
9. 合并滤液通过减压蒸馏浓缩至约240升。
10. 冷却混合物至约27℃，加入200千克甲基叔丁基醚。
11. 再搅拌7小时后过滤收集固体。
12. 用甲基叔丁基醚（40千克）洗涤滤饼，在40℃下干燥。

最终得到呈固体的7-氮杂吲哚-4-硼酸酯39.7千克，纯度为98.9%，理论摩尔数为161.0摩尔，产率为76%。

反应信息

• 作为反应物：
  描述：

  7-氮杂吲哚-4-硼酸酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 作用下， 以 1,4-二氧六环 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 3.0h， 生成 4-[7-bromo-4-(1H-pyrrolo[2,3-b]pyridin-4-yl)thieno[3,2-d]pyrimidin-2-yl]morpholine
  参考文献：
  名称：

  FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF

  摘要：

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。

  公开号：

  US20160214994A1
• 作为产物：
  描述：

  7-氮杂吲哚 在 tris-(dibenzylideneacetone)dipalladium(0) potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 生成 7-氮杂吲哚-4-硼酸酯
  参考文献：
  名称：

  WO2008/139161

  摘要：

  公开号：

文献信息

• Discovery of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors for the treatment of glaucoma
  作者：Yumeng Sun、Yueshan Li、Zhuang Miao、Ruicheng Yang、Yun Zhang、Ming Wu、Guifeng Lin、Linli Li

  DOI：10.1016/j.bmcl.2021.128138

  日期：2021.8

  associated with the pathology of glaucoma and discovery of ROCK inhibitors has attracted much attention in recent years. Herein, we report a series of 3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one derivatives as a new class of ROCK inhibitors. Structure-activity relationship studies led to the discovery of compound 12b, which showed potent activities against ROCK I and ROCK Ⅱ with IC50 values of 93 nM

  Rho 相关蛋白激酶 (ROCK) 与青光眼的病理学相关，近年来 ROCK 抑制剂的发现引起了广泛关注。在此，我们报告了一系列 3,4-二氢苯并[ f ][1,4] oxazep​​in-5(2 H )-one 衍生物作为一类新的 ROCK 抑制剂。构效关系研究导致了化合物12b的发现，该化合物对 ROCK I 和 ROCK Ⅱ具有强活性，IC 50值分别为 93 nM 和 3 nM。12b还显示出对 ROCK 的相当大的选择性。12b的平均眼压降低效果在眼压正常模型中为 34.3%，未观察到明显的充血。总的来说，这项研究为针对青光眼的 ROCK 靶向药物发现提供了一个很好的起点。
• [EN] HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE<br/>[FR] PYRROLOPYRIDINES À SUBSTITUTION HÉTÉROCYCLYLE UTILISÉES EN TANT QU'INHIBITEURS DE LA KINASE CDK12
  申请人：UNIV NOTTINGHAM

  公开号：WO2019058132A1

  公开（公告）日：2019-03-28

  This invention relates to compounds that are inhibitors of the CDK12 kinase. The compounds are useful in the treatment of disorders mediated by CDK12 kinase including myotonic dystrophy type 1 (DM1) and other disorders caused by the generation of RNA repeat expansion transcripts. In particular,the invention relates to compounds of the formula (I), or a pharmaceutically acceptable salts or N-oxides thereof, wherein R1a, R2, R3, R4a, R4b and R4c are as defined herein.

  这项发明涉及抑制CDK12激酶的化合物。这些化合物可用于治疗由CDK12激酶介导的疾病，包括1型肌强直性营养不良（DM1）和其他由RNA重复扩展转录物引起的疾病。特别是，该发明涉及公式（I）的化合物，或其药用可接受的盐或N-氧化物，其中R1a, R2, R3, R4a, R4b和R4c按本文定义。
• [EN] TRICYCLIC HETEROCYLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES TRICYCLIQUES
  申请人：MERCK PATENT GMBH

  公开号：WO2017202748A1

  公开（公告）日：2017-11-30

  Compounds of the formula (I) in which R1 and R2 have the meanings indicated in Claim 1,are inhibitors of ATR, and can be employed for the treatment of diseases such as cancer.

  式(I)中R1和R2具有权利要求书中指示的含义，是ATR的抑制剂，可用于治疗癌症等疾病。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2015058084A1

  公开（公告）日：2015-04-23

  The present application discloses compounds that are inhibitors of Btk, compounds that are inhibitors of ΡΒΚδ, and compounds that are dual inhibitors of both Btk and PI3Kδ. Also described are methods for synthesizing such inhibitors and methods for using such inhibitors for the treatment of diseases wherein inhibition of Btk and PI3Kδ provides a therapeutic benefit to a patient having the disease.

  本申请公开了抑制Btk的化合物、抑制ΡΒΚδ的化合物，以及既是Btk又是PI3Kδ的双重抑制剂的化合物。还描述了合成这些抑制剂的方法，以及利用这些抑制剂治疗疾病的方法，其中抑制Btk和PI3Kδ对患有该疾病的患者提供治疗益处。
• [EN] THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS<br/>[FR] THIÉNOPYRIMIDINES EN TANT QU'INHIBITEURS DE LA KINASE CDC7
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010101302A1

  公开（公告）日：2010-09-10

  The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.

  本发明涉及一种由式(I)表示的化合物，其中每个符号如规范中定义，或其盐，或其前药，用于预防或治疗癌症。